ÌÇÐÄvlog

For Authors

About JAMA Oncology

Mary L. (Nora) Disis, MD

Editor

• Editorial and Video Interview

JAMA Oncology is an international peer-reviewed journal and the definitive journal for scientists, clinicians, and trainees in the field of oncology. JAMA Oncology is a member of the ÌÇÐÄvlog, a consortium of peer-reviewed, general medical and specialty publications.

Journal Frequency and Access. JAMA Oncology is published online weekly, every Thursday, and in 12 print/online issues a year. The journal receives more than 7.3 million annual article views and downloads. Without any author fees, all research articles are made free access online 12 months after publication on the website. In addition, the online version is freely available or nearly so to institutions in developing countries through the World Health Organization's program.

Editorial Information. The journal’s acceptance rate is 12%. The median time to first decision is 2 days, and 53 days with review. The Journal Impact Factor is 22.3, one of the highest ranking among oncology journals. All articles are published online first. Additional information on the types of articles published and editorial policies is available in the journal's Instructions for Authors.

Editorial Team. The founding Editor in Chief of JAMA Oncology is Mary L. (Nora) Disis, MD. Dr Disis is director of the UW Institute of Translational Health Science and the Center for Translational Medicine in Women's Health. She is also associate dean of the UW School of Medicine, dean of Research and Graduate Education, associate dean of Translational Science, Helen B. Slonaker Endowed Professor for Cancer Research, professor of Medicine and Oncology, and adjunct professor of Obstetrics & Gynecology and Pathology. For a complete listing of the journal's Editors and Editorial Board, see Editors and Publishers.

Mission Statement. JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer. Our original, innovative, and timely scientific and educational content provides a deeper understanding of cancer pathogenesis and recent treatment advances for our readers. JAMA Oncology aims to effectively convey the findings of important clinical research, major scientific breakthroughs, actionable discoveries, and state-of-the-art treatment pathways to the oncology community. Our goal is that successful communication of new knowledge will ultimately translate to clinical benefit for people living with and surviving cancer.

JAMA Oncology
ISSN 2374-2437 (Print)
ISSN 2374-2445 (Online)

Back to top

Why Publish in JAMA Oncology?

JAMA Oncology is committed to publishing influential original research, opinions, and reviews that advance the science of oncology and improve the clinical care of patients with cancer.

Impact and Reach

• Journal Impact Factor of 22.3, one of the highest ranking among oncology journals
• Broad reach through related commentary, author audio interviews, podcasts, email alerts, multimedia, and more than 114,000 social media followers (Facebook, X, LinkedIn)
• More than 7.3 million annual article views and downloads
• International authors: 57% of submissions come from outside the United States
• Extensive press coverage, with over 7,900 media mentions in 2023 and 2024 in outlets such as The New York Times, The Washington Post, CNN, and Associated Press
• Top Altmetric scores—JAMA Oncology published 17 of the top 50 articles among oncology journals, including the No. 1 article
• Number of citations, Altmetric score, page views, and PDF downloads tracked for your published article

Prompt Decisions and Rapid Publication Timelines

• Highly selective peer review and editorial evaluation, with 12% acceptance rate for all submissions
• Median time to first decision: 2 days without external peer review; 53 days with review
• Expedited peer review and online publication for select clinical trials, other major studies, or reports with urgent public health importance
• Online First publication of all major articles
• Coordination with meeting presentation: Opportunity to publish new research simultaneously with your presentation

Author Service

• User-friendly manuscript submission system and process
• Prompt, expert review and consideration from our experienced editors
• Highest standards followed to improve your accepted manuscript’s accuracy, reliability, and readability
• CME credit available for lead authors who publish in JAMA Oncology
• Opportunity for your work to be augmented with expert illustration, interactive features, video, audio, and visual abstract
• Display of content on fast, device-responsive website
• Citations, views, and Altmetric score displayed with every article
• Free public access: All research articles are freely available 12 months after publication on the journal's website
• Open access: Authors of research articles may elect to pay for immediate open access on the day of publication
• Deposit to PubMed Central: The journal deposits all published research articles into PubMed Central (PMC) for authors
• Authors may post accepted research manuscripts in public repositories on or after publication provided that they link to the published article on the journal website
• Online extras: Ability to post supplemental content online and download your article’s tables and figures as PowerPoint slides
• The ÌÇÐÄvlog advantage: Authors of papers not accepted by JAMA Oncology may have the option to have their papers and reviewers' comments automatically referred to one of the ÌÇÐÄvlog specialty journals and/or ÌÇÐÄvlog Open
• Dedicated media team to promote your article to the news media and on social media

Commitment to Equity

• ÌÇÐÄvlog journals welcome manuscript submissions on equity, diversity, and inclusion (EDI).
• For more information, see the ÌÇÐÄvlog EDI Editors, Policies, and Topic Collection

For more information, see JAMA Oncology Instructions for Authors. Submit your manuscript at .

Back to top

Updated November 2024